European ScreeningPort and Merck KGaA Sign Research Agreement

News   Oct 28, 2010

 
European ScreeningPort and Merck KGaA Sign Research Agreement
 
 
 

RELATED ARTICLES

PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery Programs

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.

READ MORE

Gene Editing Technology May Improve Accuracy of Predicting Heart Disease Risk

News

Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.

READ MORE

Integrated Lead Discovery: An Evolving Toolbox

News

A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Diagnostics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy